RESEARCH 研究の報告

2025.4.30

Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancer.

著者 Hashimoto K, Kaira K, Mouri A, Shiono A, Miura Y, Yamaguchi O, Imai H, Kagamu H, Kuji I.

Transl Lung Cancer Res. 2025 Apr 30;14(4):1242-1253. doi: 10.21037/tlcr-2024-1084. Epub 2025 Apr 27.

PMID: 40386730

2025.4.1

A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

著者 Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, Yamaguchi O, Masaki K, Hashimoto K, Shiono A, Miura Y, Kobayashi K, Kaira K, Kagamu H.

Cancer Med. 2025 Apr;14(8):e70741. doi: 10.1002/cam4.70741.

PMID: 40249663

2025.2.1

Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.

著者 Matsukida A, Imai H, Shiono A, Ryuno Y, Hashimoto K, Miura YU, Endo S, Okazaki S, Yamaguchi OU, Mouri A, Abe T, Kaira K, Kobayashi K, Kato S, Kagamu H.

Anticancer Res. 2025 Feb;45(2):733-741. doi: 10.21873/anticanres.17461.

PMID: 39890195

2025.1.23

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

著者 Endo S, Imai H, Mouri A, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Nakagawa J, Kaira K, Kobayashi K, Kagamu H.

J Cancer Res Clin Oncol. 2025 Jan 23;151(1):43. doi: 10.1007/s00432-025-06089-x.

PMID: 39843575

2024.12.4

Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare Case.

著者 Mikami E, Hashimoto K, Kaira K, Mouri A, Miura Y, Shiono A, Yamaguchi O, Imai H, Kagamu H.

Cureus. 2024 Dec 4;16(12):e75079. doi: 10.7759/cureus.75079. eCollection 2024 Dec.

PMID: 39759665

2024.11.18

Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Kagamu H, Kuji I.

Cancer Imaging. 2024 Nov 18;24(1):157. doi: 10.1186/s40644-024-00800-w.

PMID: 39558409

2024.7.3

Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.

著者 Ito K, Kaira K, Imai H, Shiono A, Hashimoto K, Yamaguchi OU, Kagamu H.

Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.

PMID: 38962554 Free PMC article.

2024.7.1

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.

著者 Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H.

Curr Oncol Rep. 2024 Sep;26(9):1113-1119. doi: 10.1007/s11912-024-01571-0. Epub 2024 Jul 1.

PMID: 38954314 Review.

2023.5.8

Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.

著者 Ito K,　Yamaguchi O,　Kaira K,　Imai H,　Kagamu H.

Lung Cancer . 2023 May:179:107193. doi: 10.1016/j.lungcan.2023.107193. Epub 2023 Apr 10.

PMID: 37058785 DOI: 10.1016/j.lungcan.2023.107193